Blockchain Registration Transaction Record

InFlectis BioScience Announces Positive Results in ALS Trial Study

InFlectis BioScience reports positive results in ALS trial study, demonstrating safety and efficacy of IFB-088 in bulbar-onset ALS patients. The findings offer hope for new treatment possibilities and highlight the importance of targeting ISR and oxidative stress pathways in ALS.

This news matters as it highlights the significant progress in developing a potential treatment for ALS, a devastating disease with limited therapeutic options. The successful completion of the study demonstrates the safety and efficacy of IFB-088, bringing hope to ALS patients and paving the way for further clinical development.